Drug intelligence / Profile preview

AGM-380

Development stage: Preclinical
Lead developer: HLB PEP
Modality: Peptides

Overview

AGM-380 is a preclinical peptide-based drug candidate developed by Anygen for the treatment of viral infections. As a peptide therapeutic, it is designed to target specific viral or host factors to inhibit the viral life cycle, such as entry, replication, or assembly. Anygen, a company specializing in peptide synthesis and drug discovery, is advancing AGM-380 through early-stage research to address various viral pathogens. The candidate leverages Anygen's expertise in peptide modification to enhance stability and therapeutic potential.

Beyond the preview

Go deeper on AGM-380.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGM-380.

Explore the full profile